2026-04-23T08:10:28Zhttps://repository.urosario.edu.co/oai/request

oai:repository.urosario.edu.co:10336/238472022-05-02T07:37:14Zcom_10336_39998com_10336_563col_10336_683

Goldberg, Ronald B Rosenson, Robert S Hernandez-Triana, Eric Misir, Soamnauth Jones, Michael R 2020-05-26T00:05:59Z 2020-05-26T00:05:59Z 2013 Background: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol(LDL-C) ? 100 mg/dL (?2.6 mmol/L) and triglycerides less than 500 mg/dL ( less than 5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: ?113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly (p less than 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p less than 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles. © The Author(s) 2012. application/pdf https://doi.org/10.1177/1479164112461657 14791641 https://repository.urosario.edu.co/handle/10336/23847 eng 262 No. 3 256 Diabetes and Vascular Disease Research Vol. 10 Diabetes and Vascular Disease Research, ISSN:14791641, Vol.10, No.3 (2013); pp. 256-262 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876038812&doi=10.1177%2f1479164112461657&partnerID=40&md5=fc9033f028a90944f89390f4f59b3cbc info:eu-repo/semantics/openAccess Abierto (Texto Completo) instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR Colesevelam High density lipoprotein Lipoprotein Low density lipoprotein Low density lipoprotein cholesterol Triacylglycerol Very low density lipoprotein Article Atherogenesis Cardiovascular risk Cholelithiasis Cholesterol blood level Controlled study Cystocele Drug efficacy Drug safety Erectile dysfunction Female Human Hyperlipidemia Hypoglycemia Impaired glucose tolerance Intention to treat analysis Lipoprotein blood level Major clinical study Male Nuclear magnetic resonance spectroscopy Oral glucose tolerance test Ovary polycystic disease Particle size Patient preference Randomized controlled trial (topic) Triacylglycerol blood level Adult Allylamine Constipation Diarrhea Double-blind method Dyspepsia Female Humans Hydroxymethylglutaryl-coa reductase inhibitors Hyperlipidemias Intention to treat analysis Lipoproteins Male Particle size Prediabetic state Triglycerides Apolipoprotein Colesevelam Lipoprotein particles Low-density lipoprotein Prediabetes Primary hyperlipidaemia vldl ldl hdl biomolecular Cholesterol Lipoproteins Lipoproteins Nuclear magnetic resonance Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia article info:eu-repo/semantics/publishedVersion Artículo